Investigational drug · Phase 3
BD MDI
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Asthma.
Phase 3Last checked: Nov 19, 2026Latest source record: Jan 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
0 still active
All registered trials
10
Any phase or sponsor naming "BD MDI"
First trial start
2022
Jan 12, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BD MDI", any sponsor or status.
Conditions studied
As listed on its trial records.
- Asthma
Approved drugs for the same conditions: Asthma · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "BD MDI" as an intervention, largest first.
- Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)Pivotal-lookingCompleted
National Institute of Mental Health (NIMH)NIH
NCT00012558 · 5,000 participants · Start Sep 1998
Drug: lithium; valproate and 6 more · For: Bipolar Disorder
Sites: Stanford, California; Denver, Colorado; Boston, Massachusetts · 11 sites in all
- Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPDPivotal-lookingCompleted
Pearl Therapeutics, Inc.Industry
NCT02766608 · 2,389 participants · Start May 31, 2016 · Primary completion Dec 1, 2017
Drug: BFF MDI 320/9.6 μg; BFF MDI 160/9.6 μg and 3 more · For: Chronic Obstructive Pulmonary Disorder
Sites: Athens, Alabama; Birmingham, Alabama; Dothan, Alabama · 259 sites in all
- A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered Dose Inhaler (BDA MDI/PT027) Used 4 Times Daily in Adults and Children 4 Years of Age or Older With AsthmaPivotal-lookingCompleted
Bond Avillion 2 Development LPIndustry
NCT03847896 · 1,001 participants · Start Mar 20, 2019 · Primary completion Jul 20, 2021
Drug: Budesonide metered dose inhaler / BD MDI 160 µg; Albuterol sulfate metered dose inhaler / AS MDI 180 μg · For: Asthma
Sites: Mobile, Alabama; Bakersfield, California; Costa Mesa, California · 129 sites in all
- A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma (VATHOS)Pivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT05202262 · 645 participants · Start Jan 12, 2022 · Primary completion Feb 26, 2025
Drug: BFF MDI 320/9.6 μg; BFF MDI 160/9.6 μg and 2 more · For: Asthma
Sites: Chandler, Arizona; Tucson, Arizona; Bakersfield, California · 142 sites in all
- BETRI-Prospective: Asthma Control in Single Inhaler ICS/LABA/LAMA (87/5/9 pMDI [BDP/FF/GB - 100/6/12.5 μg]) vs Single Inhaler ICS/LABA (200/6 pMDI [BDP/FF - 200/6 μg])Pivotal-lookingRecruiting
Chiesi Farmaceutici S.p.A.Industry
NCT07666490 · 644 participants (planned) · Start Jun 28, 2026 · Primary completion Jun 13, 2028
Drug: Beclometasone dipropionate, formoterol fumarate, and glycopyrronium bromide (100/6/12.5 µg per actuation); Foster® 200/6 pMDI (BDP/FF-200/6 µg) · For: Asthma
Sites: Rousse, Bulgaria
- A 12-week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants With Inadequately Controlled Asthma (LITHOS)Pivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT05755906 · 374 participants · Start Feb 27, 2023 · Primary completion Nov 19, 2024
Drug: BFF MDI 160/9.6 μg BID (320/19.2μg/day); BD MDI 160 μg BID (320 μg/day) · For: Asthma
Sites: Chandler, Arizona; Mesa, Arizona; Tucson, Arizona · 104 sites in all
- Efficacy and Safety Study of PT009, PT008, and PT005 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)Pivotal-lookingCompleted
Pearl Therapeutics, Inc.Industry
NCT02196077 · 180 participants · Start Aug 1, 2014 · Primary completion Mar 1, 2015
Drug: BFF MDI 320/9.6 μg; BFF MDI 160/9.6 μg and 3 more · For: Chronic Obstructive Pulmonary Disease
Sites: Rolling Hills Estates, California; Clearwater, Florida; Panama City, Florida · 17 sites in all
- Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent AsthmaPivotal-lookingCompleted
Pearl Therapeutics, Inc.Industry
NCT02105012 · 147 participants · Start Apr 1, 2014 · Primary completion Sep 1, 2015
Drug: BD MDI 320 µg; BD MDI 160 µg and 3 more · For: Asthma
Sites: Athens, Alabama; Birmingham, Alabama; Foley, Alabama · 41 sites in all
- Monotherapy of Itraconazole Versus Prednisolone in Allergic Bronchopulmonary AspergillosisPivotal-lookingCompleted
Post Graduate Institute of Medical Education and Research, ChandigarhAcademic, hospital or other
NCT01321827 · 100 participants · Start Apr 2011 · Primary completion Mar 2013
Drug: Glucocorticoids; Itraconazole · For: Allergic Bronchopulmonary Aspergillosis
Sites: Chandigarh, India
AstraZenecaAstraZeneca (AZN)
NCT03772223 · 91 participants · Start Jan 21, 2019 · Primary completion May 10, 2019
Drug: Treatment A (Budesonide/Albuterol Sulfate metered dose inhaler); Treatment B (Budesonide metered dose inhaler) and 1 more · For: Healthy Volunteers
Sites: London, United Kingdom
Newest research
PubMed records naming it or its code names, newest first.
- Simulation Study on the Screening of Hydrophobic Surface Materials for Pipeline Drag Reduction Based on Adsorption Properties.
Meng J, Wang J, Wang L · Langmuir 2022
- Suboptimal glycemic control in adolescents and young adults with type 1 diabetes from 2011 to 2020 across Australia and New Zealand: Data from the Australasian Diabetes Data Network registry.
James S, Perry L, Lowe J, et al. · Pediatr Diabetes 2022
- Randomized dose-ranging study of a budesonide metered-dose inhaler by using co-suspension delivery technology in asthma.
Miller SD, Nyberg J, Siddiqui S, et al. · Allergy Asthma Proc 2018
- Budesonide/formoterol MDI with co-suspension delivery technology in COPD: the TELOS study.
Ferguson GT, Papi A, Anzueto A, et al. · Eur Respir J 2018
- Efficacy, safety, and pharmacokinetics of budesonide/formoterol fumarate delivered via metered dose inhaler using innovative co-suspension delivery technology in patients with moderate-to-severe COPD.
Kerwin EM, Siler TM, Arora S, et al. · Int J Chron Obstruct Pulmon Dis 2018
- Phase studies of a urethane model compound and polyether macroglycols by infrared spectroscopy and the relationship between eutectic composition of soft segment and blood compatibility.
Isama K, Kojima S, Nakamura A · J Biomed Mater Res 1993
Also in development for Asthma
- CM512Phase 39 trials
Keymed Biosciences Co.Ltd · Chronic Rhinosinusitis With Nasal Polyposis, Chronic Spontaneous Urticaria (CSU), Asthma
- LunsekimigSAR443765Phase 39 trials
Sanofi · Asthma, Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps
- GSK5784283Phase 38 trials
GSK · Pulmonary Disease, Chronic Obstructive, Asthma, Nasal Polyps
- PF-07275315tilrekimigPhase 38 trials
Pfizer · Atopic Dermatitis, Asthma, Moderate to Severe Chronic Obstructive Pulmonary Disease
- MG-K10Humanized Monoclonal AntibodyPhase 36 trials
Shanghai Mabgeek Biotech.Co.Ltd · Dermatitis, Atopic, Chronic Urticaria, Idiopathic, Atopic Dermatitis
- SHR-1905Phase 36 trials
Guangdong Hengrui Pharmaceutical Co., Ltd · Asthma, Chronic Rhinosinusitis With Nasal Polyps, Moderate-to-severe Atopic Dermatitis
- TozorakimabMEDI3506Phase 36 trials
AstraZeneca · Chronic Obstructive Pulmonary Disease (COPD), Asthma, Viral Lung Infection and Acute Respiratory Failure
- TQC2731Phase 35 trials
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. · Asthma, Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AstraZeneca.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.